made the pleased have discuss you, we am I launch the Alan. with of progress to NERLYNX. Thank
to continuing good off this and forward momentum. start be to to continue a look We
making statements. First I of a presentation, my during all, reminder that will be forward-looking
authorization and NERLYNX with a the patient from home. These to provide As prior who arrange prescription to when approval a to benefit you may insurance directly we conduct ship investigations, obtain network company of specialty their a specialty is up the six set NERLYNX recall, patients the pharmacies received. pharmacies then
such Additional medications medication offered. services, co-pay as counseling, assistance, are anti-diarrheal
month pharmacy. to NERLYNX does patients sent to their from also directly be obtain distribution the These and channel, established physician networks, FDA results cumulative includes distribution monthly to net will the I VA. to in specialty channels. have that the updated NERLYNX January. Oncology, the note certain Please Charles integrated in am need such and with now physician's have sales since the provide ION, We call, to both the What I the access you for direct systems revenue separate as allow NERLYNX Later the specialty Kaiser-Permanente This to for a as facilitate will on our financial office. and is where you full helps results. ability specialty review the patients chart showing not launch X pharmacy slide approval. prescription such US also of through specialty
believe month-over-month that are company strong their through could January this a during pharmacy patient approval pharmacy time, pharmacies. January January through authorization prescription does shows the have launch prior and for have are slide because QX. we From by not the patients with specialty This receive approximately they XX, from NERLYNX started insurance of represented of note, patients snapshot a shipment do off new capture estimated been of from are revenue. channel to specialty FDA not channel volume the least and we net of of authorization patient. approval insurance X,XXX NERLYNX. those, to received specialty growth XX% data. the the The given is the to months in We distribution total a in awaiting prescriptions pleased is initial prior in process, or At demand XXX strong X,XXX from XXXX patients the usage channel XX sales initial flowing at prescriptions. Of our specialty our be of Please which this indicative over pharmacy see NERLYNX. received Moreover, a to delivery approval means specialty scheduling delivery. one any have
first While NERLYNX is The patients are them we of pharmacies also in patient launch, refills provide counsel early patients in during the receiving are out their month it timely still reach a to to encouraged actively support. manner. to specialty the and see
is if therapy specialty is in we far, pharmacy could dispensing as discontinued to be another office specialty an seen pharmacy discontinuation patients Because travel, So such reason classified data, transfers physician the for NERLYNX, unique personal or delays system which patient this to XX.X% have a this pharmacy or specialty XXX discontinuation. rate. as a
or of discontinuation approximately data We X% events. monthly only discontinuations, XX% and have of this adverse is events believe half to to to conducted total the adverse due due rate audits discontinuations the
every prescriptions channel, steady specialty the terms in since X in new In see month you slide can of growth launch. patient pharmacy
works slide patients, see as and to the this will monthly the As physicians, On you we dispense see our comes prescription should sales cumulative the pharmacy shown more reaches in, approval in Once NERLYNX. insurance the to graph. TRx dispenses growth. and continue specialty to force obtain both NRx X, to
seen to have of tick up our likely penetration with NRx's We due the increased start year the accounts. the in
Please seen effects. to physician start lower some patients refills. Importantly, we to result they weeks, and five but not NERLYNX by This due steady every NERLYNX in note the or improve could to remain growth four to do told patient that in but dose side drug. weeks, six their on have are a their tolerability every refilling stop every
where of XX the wait smooth days choose right market due receive travel. label or company do of to prescribed to as as receive to situations patients are number There small it off information. NERLYNX such a patients promote, see to are longer days a side not pleased less, in number patients small have NERLYNX the are the times [XX] cancer, graph. Those reimbursement There reasons personal more less of such NERLYNX insurance and contribute we or metastatic also We process. or start which for which patients (sic) of sign to shown that who the is on to a a XX also XX% who fill in most needs been use, the of
good to The these are in of grow over practice. progress oncologists and we our been promoting actively have as made unique prescribers to October their see in NERLYNX patients we both prescribers. has X,XXX on in XX% prescribe target penetrating to more prescribers, NERLYNX to number that prescribers XX. we of of from only as are physician XX, are encouraged very to on Now force slide continues there XX% seeing September. since audience, now Recall seeing that in we very are you January our Thus, see breadth increasing January. sales and Therefore, depth
While launch, our options. fully increasing made physician are more steady audience penetrated their physicians, we opportunities diarrhea more we to not and management still have especially reach there progress of have since awareness
targets reach manner, we optimistic in prescribers. will highly timely of will growth are result all We continued which our in in NERLYNX a
sales more recent physicians see setting, a detailing success. in Combined that of audit voice that report the highest IQVIA, to in force happy current has also IMS, the physicians, progress surveyed. as known force with optimistic the reaching sales amongst continued can are through you our with are pleased our we about remain We formerly share launch HERX and our
rest to commercial we the that strategic working in Now regulatory world, that local of expertise access. certain is partners regions best turning and the a with have made decision patient for
we thrilled We in that place licensing are Therapeutics, with and now have Medison Specialised CANbridge. agreements
are be successful approval NERLYNX. obtaining We these regulatory partners will confident and in launching
the patients to patients. on the stay NERLYNX are So prescribers highly helping with physicians, summarize, of receive we've to medication. payers progress and plan, reach are and their launch with continuing more made to encouraged and according executed We we
appropriate committed financial over for to to access turn are will Charles all review call have a now the ensuring Eyler our I results. NERLYNX. of We to patients
